Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 25, 2013
Event: Entry into a Material Definitive Agreement and Amendment to Articles of Incorporation.
CorMedix Inc. entered into a securities purchase agreement with an existing institutional investor to raise capital for general corporate purposes, specifically the development and commercialization of Neutrolin, working capital, and capital expenditures. This transaction represents the company's third financing of 2013.
Key Financial Metrics and Transaction Details
Transaction Structure:
- Securities Issued: 454,546 shares of Series B Non-Voting Convertible Preferred Stock and a warrant to purchase up to 227,273 shares of common stock.
- Gross Proceeds: $500,000.
- Price: $1.10 per share of Series B stock (sold together with the warrant).
- Warrant Terms: Exercise price of $1.50 per share; five-year term; exercisable immediately.
Liquidity and Capital Strategy: The company continues to explore equity and debt issuances and strategic partnering to raise capital while considering potential dilution. No placement agent or underwriter was involved in this offering.
Material Changes and Securities Terms
Conversion and Exercise Restrictions: Both the Series B Preferred Stock and the warrant are subject to a beneficial ownership limitation. The holder is prohibited from converting or exercising if the result would cause the holder (together with affiliates) to own more than 3.99% of the total number of shares of common stock then issued and outstanding.
Liquidation Preferences: In the event of liquidation, dissolution, or winding up, Series B holders receive $0.001 per share before any distribution to common stockholders. The Series B stock ranks senior to common stock and on parity with other Series B stock.
Dividends: Series B shares are not entitled to dividends unless specifically declared by the board of directors.
Guidance, Outlook, and Risks
Closing Date: Anticipated for July 29, 2013, subject to customary closing conditions.
Use of Proceeds: Net proceeds will fund the development and commercialization of Neutrolin, working capital, and capital expenditures.
Risks: The filing notes the company's ongoing need to raise capital and the potential for dilution to existing stockholders. The transaction relies on the satisfaction of closing conditions.
Investor Verification Checklist
- Verify the closing of the transaction on or around July 29, 2013.
- Review the Certificate of Designation of Series B Non-Voting Convertible Preferred Stock (Exhibit 3.4) for full rights and preferences.
- Confirm the impact of the 3.99% beneficial ownership limitation on future liquidity for the investor.
- Monitor subsequent filings for the prospectus supplement under Rule 424(b)(5) regarding the shelf registration statement (File No. 333-185737).
- Assess the company's cash runway given this is the third financing of the year.